IL248745B - (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza - Google Patents

(s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza

Info

Publication number
IL248745B
IL248745B IL248745A IL24874516A IL248745B IL 248745 B IL248745 B IL 248745B IL 248745 A IL248745 A IL 248745A IL 24874516 A IL24874516 A IL 24874516A IL 248745 B IL248745 B IL 248745B
Authority
IL
Israel
Prior art keywords
compound
cmin
plasma
htbz
per
Prior art date
Application number
IL248745A
Other languages
English (en)
Hebrew (he)
Other versions
IL248745A0 (en
Original Assignee
Neurocrine Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences filed Critical Neurocrine Biosciences
Publication of IL248745A0 publication Critical patent/IL248745A0/en
Publication of IL248745B publication Critical patent/IL248745B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL248745A 2014-05-06 2015-05-06 (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza IL248745B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461989240P 2014-05-06 2014-05-06
PCT/US2015/029519 WO2015171802A1 (en) 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Publications (2)

Publication Number Publication Date
IL248745A0 IL248745A0 (en) 2017-01-31
IL248745B true IL248745B (en) 2022-07-01

Family

ID=53264772

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248745A IL248745B (en) 2014-05-06 2015-05-06 (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza

Country Status (24)

Country Link
US (3) US20170071932A1 (enExample)
EP (3) EP4389227A3 (enExample)
JP (4) JP6635945B2 (enExample)
KR (5) KR20220140647A (enExample)
CN (3) CN112741835A (enExample)
AU (1) AU2015256012B2 (enExample)
CA (1) CA2947736C (enExample)
CY (1) CY1125058T1 (enExample)
DK (2) DK3139925T3 (enExample)
ES (2) ES2904526T3 (enExample)
FI (1) FI3936130T3 (enExample)
HR (2) HRP20220025T1 (enExample)
HU (2) HUE066361T2 (enExample)
IL (1) IL248745B (enExample)
LT (2) LT3139925T (enExample)
MX (1) MX387625B (enExample)
NZ (1) NZ725826A (enExample)
PL (2) PL3139925T3 (enExample)
PT (2) PT3139925T (enExample)
RS (2) RS65359B1 (enExample)
RU (1) RU2753740C2 (enExample)
SI (2) SI3936130T1 (enExample)
SM (2) SMT202400199T1 (enExample)
WO (1) WO2015171802A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3875459T (lt) * 2015-10-30 2024-02-26 Neurocrine Biosciences, Inc. Valbenazino dihidrochlorido druskos ir jų polimorfai
CA3009169A1 (en) * 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
EP3473623B1 (en) 2016-06-29 2020-07-15 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal forms of nbi-98854, preparation method therefor and use thereof
JP2020500875A (ja) * 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
US10703750B2 (en) 2017-01-10 2020-07-07 Sandoz Ag Crystalline valbenazine free base
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
US10954235B2 (en) 2017-02-27 2021-03-23 Sandoz Ag Crystalline forms of valbenazine salts
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
JP2020512986A (ja) * 2017-04-01 2020-04-30 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療に使用するための（＋）−α−ジヒドロテトラベナジン
GB201705302D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705305D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
US20190111035A1 (en) * 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
CN110691596A (zh) * 2017-04-01 2020-01-14 阿德普蒂奥制药有限公司 药物组合物
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
WO2018200605A1 (en) * 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
MA50175B1 (fr) 2017-09-21 2025-05-30 Neurocrine Biosciences, Inc. Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
WO2019094491A1 (en) * 2017-11-08 2019-05-16 Yuhua Li Esters of dihydrotetrabenazine
CA3086611C (en) 2017-12-26 2023-07-25 Crystal Pharmaceutical (Suzhou) Co., Ltd. A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
CA3097189A1 (en) * 2018-04-25 2019-10-31 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
WO2019241555A1 (en) 2018-06-14 2019-12-19 Neurocrine Biosciences, Inc. Vmat2 inhibitor compounds, compositions, and methods relating thereto
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2020070236A1 (en) 2018-10-04 2020-04-09 Adeptio Pharmaceuticals Limited (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
JOP20210274A1 (ar) * 2019-05-09 2023-01-30 Neurocrine Biosciences Inc طرق لإعطاء مثبط vmat2 معين
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509336A (ja) * 2006-11-09 2010-03-25 ニューヨーク ユニバーシティ サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP3345905B1 (en) 2008-09-18 2021-09-01 Auspex Pharmaceuticals, Inc. Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2
CN106061506A (zh) * 2014-02-07 2016-10-26 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058261A1 (en) * 2006-11-08 2008-05-15 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
WO2011153157A2 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2014047167A1 (en) * 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, NEUROCRINE ANNOUNCES PHASE IIB RESULTS OF VMAT2 INHIBITOR NBI-98854 FOR TREATMENT OF TARDIVE DYSKINESIA, 9 September 2013 (2013-09-09) *

Also Published As

Publication number Publication date
AU2015256012A1 (en) 2016-11-24
IL248745A0 (en) 2017-01-31
HUE066361T2 (hu) 2024-07-28
CA2947736A1 (en) 2015-11-12
CA2947736C (en) 2023-04-18
ES2904526T3 (es) 2022-04-05
MX387625B (es) 2025-03-18
CN106456629A (zh) 2017-02-22
JP2017514850A (ja) 2017-06-08
KR20200133003A (ko) 2020-11-25
PT3139925T (pt) 2022-01-26
EP4389227A2 (en) 2024-06-26
LT3936130T (lt) 2024-04-25
KR20220140647A (ko) 2022-10-18
RU2016147523A3 (enExample) 2018-12-28
LT3139925T (lt) 2022-01-25
SMT202400199T1 (it) 2024-07-09
HUE057839T2 (hu) 2022-06-28
SI3936130T1 (sl) 2024-05-31
SI3139925T1 (sl) 2022-04-29
DK3139925T3 (da) 2021-12-20
JP2019218407A (ja) 2019-12-26
EP3139925B1 (en) 2021-12-01
HRP20220025T1 (hr) 2022-04-01
EP3936130A1 (en) 2022-01-12
EP3936130B1 (en) 2024-02-14
WO2015171802A1 (en) 2015-11-12
HRP20240459T1 (hr) 2024-06-21
JP6635945B2 (ja) 2020-01-29
SMT202200193T1 (it) 2022-07-21
US20200101063A1 (en) 2020-04-02
CY1125058T1 (el) 2023-06-09
RU2753740C2 (ru) 2021-08-23
US20170071932A1 (en) 2017-03-16
CN112741836A (zh) 2021-05-04
CN112741835A (zh) 2021-05-04
US20210196702A1 (en) 2021-07-01
JP2024153782A (ja) 2024-10-29
PL3936130T3 (pl) 2024-06-10
DK3936130T3 (da) 2024-03-25
JP2021191799A (ja) 2021-12-16
RS65359B1 (sr) 2024-04-30
EP3139925A1 (en) 2017-03-15
ES2976207T3 (es) 2024-07-26
KR20240011255A (ko) 2024-01-25
MX2016014429A (es) 2017-04-06
AU2015256012B2 (en) 2020-07-23
PL3139925T3 (pl) 2022-03-21
NZ725826A (en) 2023-05-26
PT3936130T (pt) 2024-04-17
EP4389227A3 (en) 2024-09-04
FI3936130T3 (fi) 2024-04-23
RU2016147523A (ru) 2018-06-08
KR20160147044A (ko) 2016-12-21
RS62782B1 (sr) 2022-01-31
KR20250029267A (ko) 2025-03-04

Similar Documents

Publication Publication Date Title
IL248745B (en) (s)-2-amino-3-methyl butyric acid (r2, r3, rb11)-3 azazobutyl-9,10-dimethoxy-1,3,4,6,711b-hexahydro-h2-pyrido[a-1,2 ] isoquinoline-2-yl ester for use in the treatment of Tardib Discenza
AU2021206784B2 (en) Combinations of cannabinoids and N-acylethanolamines
JP6112867B2 (ja) サキシトキシン誘導体での触覚の喪失の処置
CA2787173C (en) Methods and compositions for improved nerve conduction velocity
US20240366578A1 (en) Treatment of pain and vasoconstriction
AU2002340971B2 (en) Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
CN110300581B (zh) 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途
CA2521152A1 (en) Use of a topical medicament comprising riluzole
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
TN2020000160A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
EP1397138B1 (de) WIRKSTOFF-KOMBINATION (z.B. Galanthamin oder Desoxypeganin mit Acamprosat oder Memantin) ZUR MEDIKAMENTÖSEN SUCHT- ODER RAUSCHMITTELTHERAPIE
JP2003176240A (ja) ニコチン性アセチルコリン受容体作用薬により関節の潤滑を高める方法
WO2023141334A3 (en) Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
ZA202309969B (en) Laquinimod formulation for ocular use
CN104173332A (zh) 银杏内酯类化合物的新用途
EP2614821B1 (en) Pharmaceutical composition for treating anxiety disorder, containing n-acetyl-l-cysteine or derivative thereof
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
US20060167026A1 (en) Antipsychotic molecular-targeting epithelial growth factor receptor
KR20150109428A (ko) L-4-클로로키뉴레닌의 투여형 및 치료적 용도
JP2006508958A (ja) 抗癌剤により誘発される末梢神経障害を予防および／または処置するための医薬品
EP2265267B1 (en) Compositions comprising n-halogenated or n, n-dihalogenated amine for treatment and prophylaxis of bronchopulmonary infections
WO2021022058A3 (en) Antiarrhythmic formulation
BR112014011336A2 (pt) composições farmacêuticas que compreendem 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetra-hidro-quinolina para tratamento de doenças e condições de pele
WO2018057624A4 (en) Methods and compositions for stimulation and enhancement of regeneration of tissues
AU2004233564A1 (en) Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse